Hyperion DeFi Inc Dossier - Source-backed chat

Hyperion DeFi Inc

HYPDNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.98

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $3.66Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $56.9M

Enterprise Value $58M

Shares Outstanding 16.1M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Hyperion DeFi, Inc. (NASDAQ: HYPD) represents a unique, institutional-grade gateway bridging traditional equity markets with the high-growth decentralized finance (DeFi) ecosystem, specifically focusing on the Hyperliquid blockchain. By transitioning from its legacy biopharmaceutical roots (formerly Eyenovia, Inc.) to a dual-track model, the company has established the first U.S. publicly listed strategic treasury of Hyperliquid's native token, HYPE. The investment thesis is anchored on the rapid compounding of its HYPE treasury through native staking, validator commissions, and structured yield-enhancement strategies, which have already driven a dramatic turnaround to GAAP profitability in Q1 2026. While digital asset volatility and the wind-down of early partnerships present near-term operational adjustments, the company's aggressive capital reallocation and robust balance sheet position it for substantial long-term value creation.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$7.10

Mean target$7.20

High · most bullish analyst$7.30

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$4.0020%

A prolonged downturn in the broader cryptocurrency market severely depresses the price of HYPE, leading to substantial non-cash impairment charges on Hyperion's treasury. Operational execution of new DeFi yield strategies fails to offset the lost revenue from the terminated Native Markets and Felix agreements, causing the company to miss its FY 2026 Adjusted Gross Profit guidance. Additionally, clinical delays or regulatory hurdles for the Optejet platform increase cash burn.

Base CaseCentral scenario

$6.9550%

Hyperion successfully navigates the wind-down of its Native Markets and Felix partnerships, redeploying the 800,000 HYPE tokens into stable staking and validator operations. The company achieves its raised FY 2026 Adjusted Gross Profit guidance of $5.0 million to $7.0 million. HYPE token valuation remains stable, supporting a Net Asset Value (NAV) that closely aligns with the stock's market capitalization, while the legacy ophthalmic segment continues its development path without significant cash drain.

Bull CaseUpside scenario

$8.2530%

The Hyperliquid ecosystem continues its exponential growth, driving HYPE token prices significantly higher. Hyperion successfully reallocates its 800,000 repossessed HYPE tokens into higher-yielding DeFi monetization strategies, exceeding its raised FY 2026 Adjusted Gross Profit guidance. Concurrently, the company secures a lucrative licensing or monetization event for its proprietary Optejet ophthalmic device, providing non-dilutive capital to further expand its digital asset treasury.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Pioneering institutional gateway as the first U.S. publicly listed company building a strategic treasury of Hyperliquid's native token (HYPE).
Strong financial turnaround in Q1 2026, delivering record GAAP net income of $8.84 million and positive Adjusted EBITDA of $19.49 million.
Diversified monetization model combining native staking yield, validator commissions, and structured yield-enhancement strategies (e.g., Rysk protocol partnership).
Substantial asset backing with Gross HYPE Holdings of $71.04 million and a Net Asset Value (NAV) of $69.87 million as of March 31, 2026.

Key Investment Risks

High sensitivity to the price volatility and regulatory environment of digital assets, particularly the Hyperliquid (HYPE) token.
Concentration risk from the wind-down of major early partnerships (Native Markets and Felix Foundation), requiring rapid reallocation of 800,000 HYPE tokens.
Execution risk in deploying complex on-chain DeFi yield and volatility strategies.
Potential cash burn from the legacy clinical-stage ophthalmic technology segment (Optejet platform).

Thesis Invalidation Triggers

A catastrophic security exploit or structural failure of the Hyperliquid blockchain network.
Severe regulatory crackdowns by U.S. authorities (SEC) targeting public companies holding or staking decentralized finance tokens.
Failure to successfully redeploy the 800,000 reallocated HYPE tokens, resulting in a prolonged decline in Adjusted Gross Profit below guidance levels.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.